Anti-obesity Pharmacotherapy and Inflammation

Running, not enrolling

Conditions studied: Obesity

In brief

This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment

Key facts

Study ID

NCT05756764

Run by

Louisiana State University Health Sciences Center in New Orleans

People needed

30

Starts

2023-06-01

Expected to finish

2026-02-20

Last updated by the study team

2025-09-09

Who can join

Age: 35 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Body mass index (BMI): over 30 kg/m2
• Age: 35 to 60 years old

You may not qualify if…

• Taking medications with anti-inflammatory properties like glucocorticoids, prednisone, or non-steroidal anti-inflammatory medications, such as aspirin or Motrin Subjects on medications for long-term weight management such as phentermine-topiramate (Qsymia), orlistat (Xenical), naltrexone-bupropion (Contrave), and the glucagon-like peptide-1 receptor agonists such as liraglutide (Saxenda), and semaglutide (Wegovy).
• Prior history of cancer
• Having any clinical symptoms of systemic inflammation, acute infections such as Coronavirus disease 2019, or chronic diseases such as cancer, tuberculosis, autoimmune disease, and AIDS
• An adult unable to consent
• Prisoner
• Pregnancy or breastfeeding women

Where it is running

• LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO — New Orleans, Louisiana, United States
• Ochsner Health System - Biospecimen — New Orleans, Louisiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.